Sorry I should clarify my earlier post, too much coffee this morning and got too excited reading the ann. It says 2 more patients with stable disease which doesn't necessarily mean they were from the 4th cohort, though it seems likely given they had the highest dose so far.
The main thing like others have said is no SAE at the higher dose. Could this lead to potentially higher doses in future clinical trials?
ann: data from final cohort of patients, page-30
-
- There are more pages in this discussion • 102 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.172M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 40042144 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 10681500 | 13 |
View Market Depth
| Last trade - 16.12pm 05/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable